{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:29:58Z","timestamp":1787808598499,"version":"build-2784847793"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CSHP Foundation"},{"DOI":"10.13039\/100015569","name":"CCNA","doi-asserted-by":"crossref","award":["CNA-137794"],"award-info":[{"award-number":["CNA-137794"]}],"id":[{"id":"10.13039\/100015569","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prescribing cascades are a source of inappropriate prescribing for older adults with dementia. We aimed to study three prescribing cascades in older Nova Scotians with dementia using administrative databases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cohort entry for Nova Scotia Seniors\u2019 Pharmacare Program beneficiaries was the date of dementia diagnosis. Prescription drug dispensing data was extracted for inciting medication and second treatment (cholinesterase inhibitor and bladder anticholinergic, metoclopramide and Parkinson\u2019s disease medication, or calcium channel blocker (CCB) and diuretic) over the six-year period April 1, 2009 to March 31, 2015. In three separate analyses, dispensing an inciting medication signaled a look back of 365\u2009days from the date of first dispensing to confirm that the second treatment was started after the inciting medication. The prescribing cascade was considered when the second treatment was started within 180\u2009days of the inciting treatment. Sex differences in the prescribing cascade were tested using t-tests or chi square tests as appropriate. Both univariate (unadjusted) and multivariate (adjusted) logistic regression (adjusted for age, rurality, and sex) and Cox proportional hazards regression was used to identify risk factors for the prescribing cascade.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From March 1, 2005 to March 31, 2015, 28,953 Nova Scotia Seniors' Pharmacare beneficiaries with dementia (NSSPBD) were identified. There were 60 cases of bladder anticholinergics following cholinesterase inhibitors, 11 cases of Parkinson\u2019s disease medication following metoclopramide, and 289 cases of a diuretic following CCB in the cohort. Regression analysis demonstrated that risk of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were associated with female sex. Cox regression suggested that bladder anticholinergics were less often used by those on cholinesterase inhibitors and did not identify CCB use as leading more frequently to diuretic use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The combination of diuretics following CCB was the most common prescribing cascade and bladder anticholinergics following cholinesterase inhibitors the second most common. However, exposure to the inciting medications did not increase risk of exposure to the second treatments. Combinations of bladder anticholinergics following cholinesterase inhibitors and diuretics following CCBs were more common for women raising concern that women may be at increased risk of these prescribing cascades.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12877-021-02246-2","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:03:07Z","timestamp":1620464587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["An examination of three prescribing cascades in a cohort of older adults with dementia"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-4437","authenticated-orcid":false,"given":"Shanna C.","family":"Trenaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-3222","authenticated-orcid":false,"given":"Susan K.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7514-8972","authenticated-orcid":false,"given":"Melissa K.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"8966","key":"2246_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0140-6736(95)92656-9","volume":"346","author":"PA Rochon","year":"1995","unstructured":"Rochon PA, Gurwitz JH. Drug therapy. Lancet Lond Engl. 1995 Jul 1;346(8966):32\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(95)92656-9.","journal-title":"Lancet Lond Engl"},{"issue":"10081","key":"2246_CR2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/S0140-6736(17)31188-1","volume":"389","author":"PA Rochon","year":"2017","unstructured":"Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet Lond Engl. 2017;389(10081):1778\u201380.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"2246_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jgs.15800","volume":"67","author":"LM McCarthy","year":"2019","unstructured":"McCarthy LM, Visentin JD, Rochon PA. Assessing the scope and appropriateness of prescribing cascades. J Am Geriatr Soc. 2019;67(5):1023\u20136. https:\/\/doi.org\/10.1111\/jgs.15800.","journal-title":"J Am Geriatr Soc"},{"key":"#cr-split#-2246_CR4.1","doi-asserted-by":"crossref","unstructured":"Huh Y, Kim D-H, Choi M, Park J-H, Kwon D-Y, Jung J-H, et al. Metoclopramide and Levosulpiride Use and Subsequent Levodopa Prescription in the Korean Elderly: The Prescribing Cascade. J Clin Med. 2019;8","DOI":"10.3390\/jcm8091496"},{"key":"#cr-split#-2246_CR4.2","unstructured":"(9) [cited 2019 Dec 19]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6780178\/."},{"issue":"3","key":"2246_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1715163516640811","volume":"149","author":"PV Nguyen","year":"2016","unstructured":"Nguyen PV, Spinelli C. Prescribing cascade in an elderly woman. Can Pharm J CPJ Rev Pharm Can RPC. 2016;149(3):122\u20134. https:\/\/doi.org\/10.1177\/1715163516640811.","journal-title":"Can Pharm J CPJ Rev Pharm Can RPC."},{"issue":"5","key":"2246_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.japh.2018.06.014","volume":"58","author":"SM Vouri","year":"2018","unstructured":"Vouri SM, Van Tuyl JS, Olsen MA, Xian H, Schootman M. An Evaluation of a Potential Calcium Channel Blocker \u2013 Lower Extremity Edema \u2013 Loop Diuretic Prescribing Cascade. J Am Pharm Assoc JAPhA. 2018;58(5):534\u2013539.e4.","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"3","key":"2246_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3233\/JRS-160728","volume":"28","author":"J Le Noury","year":"2016","unstructured":"Le Noury J, Nardo JM, Healy D, Jureidini J, Raven M, Tufanaru C, et al. Study 329 continuation phase: safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. Int J Risk Saf Med. 2016;28(3):143\u201361. https:\/\/doi.org\/10.3233\/JRS-160728.","journal-title":"Int J Risk Saf Med"},{"issue":"4","key":"2246_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4140\/TCP.n.2020.148","volume":"35","author":"SM Vouri","year":"2020","unstructured":"Vouri SM. Rhinorrhea as a result of Alzheimer\u2019s disease treatment. Sr Care Pharm. 2020 Apr 1;35(4):148\u20139. https:\/\/doi.org\/10.4140\/TCP.n.2020.148.","journal-title":"Sr Care Pharm"},{"issue":"7","key":"2246_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1001\/archinte.165.7.808","volume":"165","author":"SS Gill","year":"2005","unstructured":"Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005 Apr 11;165(7):808\u201313. https:\/\/doi.org\/10.1001\/archinte.165.7.808.","journal-title":"Arch Intern Med"},{"issue":"6","key":"2246_CR10","first-page":"3","volume":"25","author":"M Rotermann","year":"2014","unstructured":"Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medication use by Canadians aged 6 to 79. Health Rep. 2014;25(6):3\u20139.","journal-title":"Health Rep"},{"key":"2246_CR11","volume-title":"Drug Use Among Seniors in Canada, 2016","author":"Canadian Institute of Health Information","year":"2016","unstructured":"Canadian Institute of Health Information. Drug Use Among Seniors in Canada, 2016. 2016. Available from: www.cihi.ca"},{"key":"2246_CR12","doi-asserted-by":"crossref","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17 [cited 2019 Dec 14]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5635569\/.","DOI":"10.1186\/s12877-017-0621-2"},{"issue":"6","key":"2246_CR13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1345\/aph.1M657","volume":"44","author":"BC Lund","year":"2010","unstructured":"Lund BC, Carnahan RM, Egge JA, Chrischilles EA, Kaboli PJ. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44(6):957\u201363. https:\/\/doi.org\/10.1345\/aph.1M657.","journal-title":"Ann Pharmacother"},{"issue":"22","key":"2246_CR14","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.286.22.2823","volume":"286","author":"C Zhan","year":"2001","unstructured":"Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. Jama. 2001;286(22):2823\u20139. https:\/\/doi.org\/10.1001\/jama.286.22.2823.","journal-title":"Jama."},{"issue":"4","key":"2246_CR15","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1111\/ajag.12712","volume":"38","author":"J Mullan","year":"2019","unstructured":"Mullan J, Burns P, Mohanan L, Lago L, Jordan M, Potter J. Hospitalisation for medication misadventures among older adults with and without dementia: a 5-year retrospective study. Australas J Ageing. 2019 Dec;38(4):e135\u201341. https:\/\/doi.org\/10.1111\/ajag.12712.","journal-title":"Australas J Ageing"},{"issue":"8","key":"2246_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/14740338.2018.1497156","volume":"17","author":"TC Eshetie","year":"2018","unstructured":"Eshetie TC, Nguyen TA, Gillam MH, Kalisch Ellett LM. A narrative review of problems with medicines use in people with dementia. Expert Opin Drug Saf. 2018;17(8):825\u201336. https:\/\/doi.org\/10.1080\/14740338.2018.1497156.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"2246_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165757","volume":"11","author":"N Parameswaran Nair","year":"2016","unstructured":"Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, et al. Prediction of hospitalization due to adverse drug reactions in elderly community-dwelling patients (the PADR-EC score). PLoS One. 2016;11(10):e0165757. https:\/\/doi.org\/10.1371\/journal.pone.0165757.","journal-title":"PLoS One"},{"key":"2246_CR18","unstructured":"Kanagaratnam L, Drame M, Novella JL, Trenque T, Joachim C, Nazeyrollas P, et al. Risk Factors for Adverse Drug Reactions in Older Subjects Hospitalized in a Dedicated Dementia Unit. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2016;85:56\u201363."},{"issue":"10","key":"2246_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40266-014-0206-0","volume":"31","author":"L Kanagaratnam","year":"2014","unstructured":"Kanagaratnam L, Mahmoudi R, Novella J-L, Jolly D, Dram\u00e9 M, Trenque T. Adverse drug reactions in elderly subjects hospitalized in a specialized dementia management unit. Drugs Aging. 2014 Oct;31(10):769\u201376. https:\/\/doi.org\/10.1007\/s40266-014-0206-0.","journal-title":"Drugs Aging"},{"issue":"4","key":"2246_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2174\/1568026619666190128125912","volume":"19","author":"M Saxena","year":"2019","unstructured":"Saxena M, Dubey R. Target enzyme in Alzheimer\u2019s disease: Acetylcholinesterase inhibitors. Curr Top Med Chem. 2019;19(4):264\u201375. https:\/\/doi.org\/10.2174\/1568026619666190128125912.","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"2246_CR21","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain J Neurol. 2018;141(7):1917\u201333.","journal-title":"Brain J Neurol"},{"issue":"4","key":"2246_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1345\/aph.18211","volume":"33","author":"WJ Krall","year":"1999","unstructured":"Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother. 1999 Apr;33(4):441\u201350. https:\/\/doi.org\/10.1345\/aph.18211.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2246_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar A, Singh A. Ekavali. A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep. 2015 Apr;67(2):195\u2013203. https:\/\/doi.org\/10.1016\/j.pharep.2014.09.004.","journal-title":"Pharmacol Rep"},{"key":"2246_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0404.1993.tb04245.x","volume":"149","author":"L H\u00e5kansson","year":"1993","unstructured":"H\u00e5kansson L. Mechanism of action of cholinesterase inhibitors in Alzheimer\u2019s disease. Acta Neurol Scand Suppl. 1993;149:7\u20139. https:\/\/doi.org\/10.1111\/j.1600-0404.1993.tb04245.x.","journal-title":"Acta Neurol Scand Suppl"},{"issue":"8","key":"2246_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.bjp.0706147","volume":"144","author":"KJ Mansfield","year":"2005","unstructured":"Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005 Apr;144(8):1089\u201399. https:\/\/doi.org\/10.1038\/sj.bjp.0706147.","journal-title":"Br J Pharmacol"},{"issue":"s1","key":"2246_CR26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0773.1978.tb03222.x","volume":"43","author":"C Sj\u00f6gren","year":"1978","unstructured":"Sj\u00f6gren C. The effects of Anticholinergics on the urinary bladder mechanism. Acta Pharmacol Toxicol (Copenh). 1978;43(s1):69\u201373.","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"2246_CR27","volume-title":"StatPearls","author":"S Isola","year":"2020","unstructured":"Isola S, Adams N. Metoclopramide. In: StatPearls. Treasure Island: StatPearls Publishing; 2020. [cited 2020 Sep 18]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519517\/."},{"issue":"5","key":"2246_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cjca.2017.03.005","volume":"33","author":"AA Leung","year":"2017","unstructured":"Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada\u2019s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5):557\u201376. https:\/\/doi.org\/10.1016\/j.cjca.2017.03.005.","journal-title":"Can J Cardiol."},{"issue":"5","key":"2246_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","volume":"34","author":"KA Nerenberg","year":"2018","unstructured":"Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018;34(5):506\u201325. https:\/\/doi.org\/10.1016\/j.cjca.2018.02.022.","journal-title":"Can J Cardiol"},{"issue":"7","key":"2246_CR30","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1097\/HJH.0b013e3283472643","volume":"29","author":"H Makani","year":"2011","unstructured":"Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011 Jul;29(7):1270\u201380. https:\/\/doi.org\/10.1097\/HJH.0b013e3283472643.","journal-title":"J Hypertens"},{"key":"2246_CR31","volume-title":"Norvasc Monograph","author":"Norvasc Monograph","year":"2017","unstructured":"Norvasc Monograph. Norvasc Monograph. 2017 [cited 2019 Dec 17]. Available from: https:\/\/www.pfizermedicalinformation.ca\/en-ca\/norvasc#."},{"issue":"4","key":"2246_CR32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1524-6175.2003.02402.x","volume":"5","author":"DA Sica","year":"2003","unstructured":"Sica DA. Calcium channel blocker-related periperal edema: can it be resolved? J Clin Hypertens Greenwich Conn. 2003;5(4):291\u20134, 297. https:\/\/doi.org\/10.1111\/j.1524-6175.2003.02402.x.","journal-title":"J Clin Hypertens Greenwich Conn."},{"issue":"11","key":"2246_CR33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","volume":"15","author":"G Leonetti","year":"2002","unstructured":"Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002 Nov;15(11):932\u201340. https:\/\/doi.org\/10.1016\/S0895-7061(02)03000-5.","journal-title":"Am J Hypertens"},{"issue":"9 Pt 1","key":"2246_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0895-7061(01)02178-1","volume":"14","author":"FH Messerli","year":"2001","unstructured":"Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens. 2001;14(9 Pt 1):978\u20139. https:\/\/doi.org\/10.1016\/S0895-7061(01)02178-1.","journal-title":"Am J Hypertens"},{"issue":"6","key":"2246_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11886-002-0110-9","volume":"4","author":"FH Messerli","year":"2002","unstructured":"Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep. 2002 Nov;4(6):479\u201382. https:\/\/doi.org\/10.1007\/s11886-002-0110-9.","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"2246_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/17425255.2017.1325873","volume":"13","author":"E Reeve","year":"2017","unstructured":"Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651\u201368. https:\/\/doi.org\/10.1080\/17425255.2017.1325873.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2246_CR37","volume-title":"Calcium Channel blockers co-prescribed with loop diuretics: a potential marker of poor prescribing? Drugs aging","author":"HJ Woodford","year":"2019","unstructured":"Woodford HJ. Calcium Channel blockers co-prescribed with loop diuretics: a potential marker of poor prescribing? Drugs aging; 2019."},{"issue":"11","key":"2246_CR38","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/jgs.15543","volume":"66","author":"H Brath","year":"2018","unstructured":"Brath H, Mehta N, Savage RD, Gill SS, Wu W, Bronskill SE, et al. What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J Am Geriatr Soc. 2018;66(11):2079\u201385. https:\/\/doi.org\/10.1111\/jgs.15543.","journal-title":"J Am Geriatr Soc"},{"key":"2246_CR39","unstructured":"Medical Services Insurance Annual Statistical Tables 12 Months Ending. 2016."},{"key":"2246_CR40","unstructured":"Dementia Strategy [Internet]. 2015 [cited 2020 Jan 28]. Available from: https:\/\/novascotia.ca\/dhw\/dementia\/"},{"key":"2246_CR41","unstructured":"Nova Scotia Postal Codes [Internet]. 2001 [cited 2019 Dec 18]. Available from: https:\/\/www.businesssellcanada.com\/sale\/cpc\/pc_b.htm"},{"issue":"5","key":"2246_CR42","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamainternmed.2019.7087","volume":"180","author":"RD Savage","year":"2020","unstructured":"Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, et al. Evaluation of a common prescribing Cascade of Calcium Channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020 May 1;180(5):643\u201351. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7087.","journal-title":"JAMA Intern Med"},{"key":"2246_CR43","doi-asserted-by":"publisher","unstructured":"Singh S, Cocoros NM, Haynes K, Nair VP, Harkins TP, Rochon PA, Platt R, Dashevsky I, Reynolds J, Mazor KM, Bloomstone S, Anzuoni K, Crawford SL, Gurwitz JH. Identifying prescribing cascades in Alzheimer's disease and related dementias: The calcium channel blocker-diuretic prescribing cascade. Pharmacoepidemiol Drug Saf. 2021. https:\/\/doi.org\/10.1002\/pds.5230. Epub ahead of print.","DOI":"10.1002\/pds.5230"},{"key":"2246_CR44","doi-asserted-by":"publisher","unstructured":"Singh S, Cocoros NM, Haynes K, Nair VP, Harkins TP, Rochon PA, Platt R, Dashevsky I, Reynolds J, Mazor KM, Bloomstone S, Anzuoni K, Crawford SL, Gurwitz JH. Antidopaminergic-Antiparkinsonian Medication Prescribing Cascade in Persons with Alzheimer's Disease. J Am Geriatr Soc. 2021. https:\/\/doi.org\/10.1111\/jgs.17013. Epub ahead of print.","DOI":"10.1111\/jgs.17013"},{"issue":"5","key":"2246_CR45","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1532-5415.2007.01143.x","volume":"55","author":"JM Starr","year":"2007","unstructured":"Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer\u2019s disease. J Am Geriatr Soc. 2007;55(5):800\u20131. https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01143.x.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2246_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/pds.3741","volume":"24","author":"E Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger E, Marum RV, Souverein P, Carmichael P-H, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015;24(3):276\u201385. https:\/\/doi.org\/10.1002\/pds.3741.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"2246_CR47","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17474124.2019.1645594","volume":"13","author":"M Shakhatreh","year":"2019","unstructured":"Shakhatreh M, Jehangir A, Malik Z, Parkman HP. Metoclopramide for the treatment of diabetic gastroparesis. Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):711\u201321. https:\/\/doi.org\/10.1080\/17474124.2019.1645594.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"2246_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2009.04189.x","volume":"31","author":"AS Rao","year":"2010","unstructured":"Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010 Jan;31(1):11\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04189.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"2246_CR49","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/archinte.1989.00390110070015","volume":"149","author":"LG Miller","year":"1989","unstructured":"Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov;149(11):2486\u201392. https:\/\/doi.org\/10.1001\/archinte.1989.00390110070015.","journal-title":"Arch Intern Med"},{"issue":"3 Suppl 1","key":"2246_CR50","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1097\/00005344-200000001-00005","volume":"35","author":"MB Andr\u00e9sd\u00f3ttir","year":"2000","unstructured":"Andr\u00e9sd\u00f3ttir MB, van Hamersvelt HW, van Helden MJ, van de Bosch WJ, Valk IM, Huysmans FT. Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-Centre study. J Cardiovasc Pharmacol. 2000;35(3 Suppl 1):S25\u201330. https:\/\/doi.org\/10.1097\/00005344-200000001-00005.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"2246_CR51","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.clinthera.2012.08.003","volume":"34","author":"G-C Oh","year":"2012","unstructured":"Oh G-C, Lee H-Y, Kang H-J, Zo J-H, Choi D-J, Oh B-H. Quantification of pedal edema during treatment with S(\u2212)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical trial. Clin Ther. 2012 Sep;34(9):1940\u20137. https:\/\/doi.org\/10.1016\/j.clinthera.2012.08.003.","journal-title":"Clin Ther"},{"issue":"1","key":"2246_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement J Alzheimers Assoc. 2013;9(1):63\u201375.e2.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"2246_CR53","doi-asserted-by":"crossref","unstructured":"Andrew MK, Tierney MC. The puzzle of sex, gender and Alzheimer\u2019s disease: Why are women more often affected than men? Womens Health. 2018;14 [cited 2020 Sep 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6311541\/.","DOI":"10.1177\/1745506518817995"},{"issue":"9","key":"2246_CR54","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1111\/bcp.13976","volume":"85","author":"SW Narayan","year":"2019","unstructured":"Narayan SW, Pearson S, Litchfield M, Le Couteur DG, Buckley N, McLachlan AJ, et al. Anticholinergic medicines use among older adults before and after initiating dementia medicines. Br J Clin Pharmacol. 2019;85(9):1957\u201363. https:\/\/doi.org\/10.1111\/bcp.13976.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2246_CR55","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/j.1532-5415.2004.52563.x","volume":"52","author":"RM Carnahan","year":"2004","unstructured":"Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004 Dec;52(12):2082\u20137. https:\/\/doi.org\/10.1111\/j.1532-5415.2004.52563.x.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"2246_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40266-017-0510-6","volume":"35","author":"LK Triantafylidis","year":"2018","unstructured":"Triantafylidis LK, Clemons JS, Peron EP, Roefaro J, Zimmerman KM. Brain over bladder: a systematic review of dual cholinesterase inhibitor and urinary anticholinergic use. Drugs Aging. 2018;35(1):27\u201341. https:\/\/doi.org\/10.1007\/s40266-017-0510-6.","journal-title":"Drugs Aging"},{"issue":"5","key":"2246_CR57","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink KM, Thomas J, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(5):847\u201353. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01681.x.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"2246_CR58","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"By the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2246_CR59","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","volume":"44","author":"D O\u2019Mahony","year":"2015","unstructured":"O\u2019Mahony D, O\u2019Sullivan D, Byrne S, O\u2019Connor MN, Ryan C, Gallagher P. STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213\u20138. https:\/\/doi.org\/10.1093\/ageing\/afu145.","journal-title":"Age Ageing"},{"issue":"22","key":"2246_CR60","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.1995.03530220046031","volume":"274","author":"J Avorn","year":"1995","unstructured":"Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa therapy following metoclopramide use. JAMA. 1995 Dec 13;274(22):1780\u20132. https:\/\/doi.org\/10.1001\/jama.1995.03530220046031.","journal-title":"JAMA."},{"issue":"9","key":"2246_CR61","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens Greenwich Conn. 2004;6(9):532\u201340. https:\/\/doi.org\/10.1111\/j.1524-6175.2004.03789.x.","journal-title":"J Clin Hypertens Greenwich Conn"},{"issue":"5","key":"2246_CR62","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.3256","volume":"21","author":"SD Berry","year":"2012","unstructured":"Berry SD, Mittleman MA, Zhang Y, Solomon DH, Lipsitz LA, Mostofsky E, et al. New loop diuretic prescriptions may be an acute risk factor for falls in the nursing home. Pharmacoepidemiol Drug Saf. 2012 May;21(5):560\u20133. https:\/\/doi.org\/10.1002\/pds.3256.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2246_CR63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/ageing\/29.6.489","volume":"29","author":"J Kelly","year":"2000","unstructured":"Kelly J, Chamber J. Inappropriate use of loop diuretics in elderly patients. Age Ageing. 2000 Nov;29(6):489\u201393. https:\/\/doi.org\/10.1093\/ageing\/29.6.489.","journal-title":"Age Ageing"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-021-02246-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02246-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T12:29:26Z","timestamp":1699014566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02246-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2246"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02246-2","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was provided by the Nova Scotia Health Research Ethics Board (NSHA REB ROMEO FILE #: 1023625). The data used in this study was anonymized before its use.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"297"}}